Coronado Biosciences Announces Initiation of Phase 2 Study Evaluating TSO in Ulcerative Colitis

Published: Sep 12, 2013

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

BURLINGTON, Mass., Sept. 12, 2013 (GLOBE NEWSWIRE) -- Coronado Biosciences, Inc. (Nasdaq:CNDO), a biopharmaceutical company focused on the development of novel immunotherapy biologic agents for the treatment of autoimmune diseases and cancer, announced today the initiation of a National Institutes of Health (NIH)-sponsored phase 2 study evaluating TSO (Trichuris suis ova or CNDO-201) for the treatment of ulcerative colitis (UC). This multi-center study will be conducted by the Autoimmunity Centers of Excellence (ACE), which are funded through a multi-million dollar grant from the National Institute of Allergy and Infectious Diseases (NIAID), part of the NIH.

Help employers find you! Check out all the jobs and post your resume.

Back to news